89,989 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by OLD Mission Capital LLC

OLD Mission Capital LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 89,989 shares of the biopharmaceutical company's stock, valued at approximately $1,651,000. OLD Mission Capital LLC owned about 0.05% of ACADIA Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of ACAD. BNP Paribas Financial Markets grew its position in shares of ACADIA Pharmaceuticals by 259.0% during the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company's stock worth $3,439,000 after acquiring an additional 161,331 shares during the last quarter. PDT Partners LLC acquired a new stake in ACADIA Pharmaceuticals in the third quarter valued at $203,000. State Street Corp boosted its position in shares of ACADIA Pharmaceuticals by 3.0% during the 3rd quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company's stock worth $91,878,000 after purchasing an additional 173,084 shares in the last quarter. Barclays PLC grew its stake in shares of ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after purchasing an additional 154,854 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of ACADIA Pharmaceuticals by 1.1% in the third quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company's stock valued at $44,234,000 after purchasing an additional 30,826 shares during the period. Hedge funds and other institutional investors own 96.71% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ACAD shares. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Morgan Stanley reiterated an "equal weight" rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, March 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $23.93.

ACADIA Pharmaceuticals Stock Down 3.0 %

Shares of NASDAQ ACAD traded down $0.47 during midday trading on Monday, hitting $14.91. The stock had a trading volume of 524,749 shares, compared to its average volume of 1,832,916. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $20.68. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of 18.88 and a beta of 0.54. The company has a fifty day moving average price of $18.14 and a 200 day moving average price of $17.05.

Insider Activity

In other news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the sale, the executive vice president now owns 56,889 shares of the company's stock, valued at approximately $969,957.45. The trade was a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now directly owns 17,595 shares of the company's stock, valued at $320,756.85. This trade represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,433 shares of company stock worth $187,319 over the last ninety days. Corporate insiders own 28.30% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.